




EXPLORING VISCERAL ADIPOSITY INDEX AS A PREDICTOR OF VISCERAL ADIPOSITY 
DYSFUNCTION AND EVALUATING ITS PERFORMANCE IN PREDICTING HEPATIC INSULIN 
RESISTANCE IN INDIAN TYPE 2 DIABETICS 
 
KAUSHAL Y. PATHAK*, ANOOKH MOHANAN, SHIVANI ACHARYA, DIVYESH MANDAVIA, HEMANT R. JADHAV 
1,3,4Clinical Research Department, Torrent Pharmaceuticals Limited, Village-Bhat, Dist. Gandhinagar, India, 2Techno-Commercial 
Department, Torrent Pharmaceuticals Limited, Village Bhat, Dist. Gandhinagar, India, 5
Received: 04 May 2016 Revised and Accepted: 20 Jun 2016 
Department of Pharmacy, Birla Institute of 
Technology and Science Pilani, Pilani Campus, Rajasthan 333031, India 
Email: kaushalpath@gmail.com   
ABSTRACT 
Objective: Visceral adiposity index (VAI) is a simple clinical algorithm developed as a surrogate marker for characterizing visceral adiposity 
dysfunction (VAD). This study aimed to explore an optimal VAI cut off value for predicting VAD as reflected quantitatively by magnetic resonance 
imaging (MRI) and to evaluate its merit in predicting the severity of the cardiometabolic risk (CMR) in type 2 diabetic patients of India. 
Methods: Data was collected from 81 diabetics and 48 healthy participants, who underwent metabolic assessments. VAI derived using BMI, waist 
circumference (WC), triglycerides (TG) and HDLc, was studied against visceral fat area measuring ≥130 cm2 by MRI as it is associated with higher CMR 
through raised VAD. Optimal VAI cutoff was determined using the area under the receiver operator characteristic curve (AUROC). Diabetic participants 
were divided into VAD absent, and VAD present groups based on derived VAI cut off to study associated difference in their metabolic profile.  
Results: Diabetic group had significantly deranged metabolic profile compared to the healthy control group. Most of the diabetic group participants 
had a visceral fat area between 101 and 200 cm2. From the ROC curve analysis (AUROC = 0.761), VAI cut-off of 2.0 predicted VAD with sensitivity 
and specificity of 73.21% and 71.23% respectively. Diabetic participants with VAI values more than 2, had significantly (p<0.05) higher WC, visceral 
fat, fasting insulin, HOMA-IR (Homeostatic model assessment for insulin resistance), TG (p<0.01), non-HDLc and apolipoprotein B/A1 ratio values. 
Age adjusted partial correlation analysis showed a significant (p<0.01) positive correlation between VAI and HOMA-IR.  
Conclusion: VAI was useful in predicting VAD and identifying the severity of CMR within type 2 diabetics. VAI can replace imaging procedures with 
the advantages of reduced economic burden and can be used as screening tool for surveillance of CMR in Indian population.  
© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (




Metabolic diseases such as diabetes and cardiovascular disease 
(CVD) are extremely prevalent in obese patients than among 
normal-weight individuals. Obesity is a remarkably heterogeneous 
condition, and not every obese patient is characterized by co-
morbidities. In this regard, increased accumulation of visceral fat 
leading to visceral adipose dysfunction (VAD) is a major link with a 
cluster of diabetogenic, atherogenic, prothrombic and pro-
inflammatory metabolic abnormalities [1]. VAD causes release of 
various cytokines and hormones, such as adiponectin, leptin, tumor 
necrosis factor, resistin and interleukin 6. Due to its anatomic 
location and peculiar metabolic, hyperlipolytic activity, the 
expanded visceral adipose depot is considered to be an independent 
component of cardiometabolic risk (CMR) [1]. It is well established 
that type 2 diabetes significantly increases the risk of CVD and that 
merely treating hyperglycemia do not eliminate all the excess 
cardiovascular risk [2]. Gastaldelli et al. explored metabolic effects of 
visceral fat accumulation in type 2 diabetes using two specialized 
techniques viz. magnetic resonance imaging (MRI) and euglycemic 
insulin clamp and reported that visceral fat had a significant 
negative impact over glycemic control through a decrease in 
peripheral insulin sensitivity and an enhancement of 
gluconeogenesis. Further, while ethnicity, gender, age, duration of 
diabetes, and obesity (as body mass index) together explained only 
25% of HbA1c variability; the inclusion of visceral fat in the model 
raised the explicable HbA1c variability to 45%. According to this 
model, HbA1c is predicted to be 0.8% higher for each 50-cm2
India is a global leader in diabetes, currently with second largest pool 
of diabetes in the world. Asian Indian phenotype is uniquely 
predisposed to develop diabetes and represents the population with 
increased abdominal adiposity (especially visceral adiposity) 
predisposing them to higher CMR compared to Caucasians at the same 
levels of BMI [5]. Excess of fat in the abdominal region is reported to 
be a better predictor of risk factors (dyslipidemia, glucose intolerance, 
and hyperinsulinemia) than the total amount of adipose tissue [6]. 
Indian diabetes federation (IDF) recommends CT and MRI for 
assessing visceral fat accumulation, where MRI is considered to be the 
gold standard in estimating visceral fat values non-invasively [7,8]. 
The association between CMR factors and visceral fat values measured 
using these techniques is stronger than the associations observed with 
waist to hip ratio and waist circumference [6].  
 
increment in the visceral fat area. Thus, an accurate measurement of 
visceral fat is an important part of clinical phenotyping and has 
rather direct consequences for the metabolic control of patients with 
type 2 diabetes [3]. Since then, with advancement in imaging 
techniques such as computed tomography (CT) and MRI, it is clearly 
demonstrated that obese diabetic patients with raised metabolic 
abnormalities like high insulin resistance and atherogenic 
dyslipidemia associated with an excess visceral adiposity are 
predisposed to higher CVD risk [4].  
Using CT and MRI techniques, diagnostic thresholds have been 
established. Presently, the visceral fat threshold is 100 cm2 below 
which disturbances of glucose, insulin and lipid metabolism are 
uncommon. Secondly, a level of 130 cm2
Although CT or MRI is precise, they have certain limitations. CT 
imaging exposes the subject to ionizing radiation while MRI is not 
done routinely in clinical practice as the setup is not available at all 
centers and further high cost involved in scan acquisition, and 
analysis restricts its use in research setting. However, MRI is a safe, 
accurate and precise imaging modality for measuring visceral 
 often detects the metabolic 
abnormalities representing an increased risk group [9-11].  
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adipose tissue, making it a favorable alternative to CT for 
quantification of visceral fat values [12].  
Recently, to identify a routinely applicable indicator of VAD having 
higher sensitivity and specificity than classical parameters (such as 
waist circumference, BMI and lipids), Amato et al. came up with 
visceral adiposity index (VAI). It is a gender-specific mathematical 
index based on simple anthropometric [BMI and waist 
circumference (WC)] and metabolic [triglycerides (TG) and HDLc] 
parameters. It is a surrogate marker of adipose tissue function and 
distribution, independently linked to insulin sensitivity and CMR in 
the general population [13-15].  
Although VAI was modeled in Caucasian population, several studies 
have been carried out in different races (Chinese, Sicilian, Japanese 
and Caucasians) to explore and validate VAI cut offs in determining 
metabolic risk [16, 17]. To our knowledge, no such study is done in 
context to the Indian population. Therefore, the aim of this present 
study was to evaluate whether VAI could become a surrogate marker 
for abdominal MRI scanning and predict the severity of metabolic 
abnormalities and insulin resistance in Indian type 2 diabetic subjects. 
MATERIALS AND METHODS 
Participants  
We analysed data from participants recruited for human metabolic 
studies from primary and secondary care hospitals. For the study, all 
participants gave written informed consent, and ethical approval 
was obtained from the respective local ethics committee. Data was 
obtained for healthy controls and individuals with diabetes being 
overweight/obese (BMI 23-35 kg/m2), with a waist circumference 
≥80 cm in females and ≥90 cm in males . For diabetes group, the 
participants selected were either newly diagnosed or diagnosed case 
of diabetes, not on any antidyslipidemic medications.  
We excluded data for participants with a history of type 1 diabetes 
mellitus, pregnancy, any significant history of endocrine, 
cardiovascular, renal or hepatic disease and standard MR 
contraindications. Similarly, data for other causes of chronic liver 
disease were excluded by taking a careful alcohol and drug history 
and performing hepatitis serology. Moreover, data for participants 
with alcohol intake>20 ml/day ethanol and any individuals with a 
history of alcohol excess were not considered.  
Anthropometric assessments 
BMI was calculated in kg/m2
Biochemical assessments included estimation of glycemic 
parameters (fasting glucose, fasting insulin, glycosylated 
hemoglobin) and lipid parameters (total cholesterol, TG, LDLc, HDLc, 
non-HDLc, apolipoprotein B, apolipoprotein A1). Routine laboratory 
markers were measured from venous blood samples using standard 
methods in the central research laboratory. 
; waist circumference was measured 
midway between the lower rib margin and the iliac crest. 
Biochemical assessments 
Estimation of abdominal fat by MRI  
Abdominal fat (visceral and subcutaneous) measurement was done 
by using single slice axial measurement at the Level of L4-L5 using 
3-Tesla MRI. The images were converted into files compatible with 
commercial image analysis software (SliceOmatic). Abdominal fat 
segmentation was done based on intensity histogram. The fat 
segment was further divided into subcutaneous and visceral 
compartments by drawing the contours. The visceral adipose tissue 
was then quantified. Visceral fat content (cm2) was quantified but 
also coded ordinal as no VAD (<130 cm2) or present (≥130 cm 2). 
Between visceral fat area of 100 cm2 and 130 cm2, the latter was 
chosen as a representative of further cardio-metabolic disturbances 
in type 2 diabetic patients. 
Calculation 
VAI score was calculated using the following sex-specific equations, 
where TG levels expressed in mmol/l and HDLc levels expressed in 
mmol/l [13]:  
Males: VAI = (WC/39.68+(1.88 × BMI)) X (TG/1.03) X (1.31/HDL) 
Females: VAI = (WC/36.58+(1.89 × BMI)) X (TG/0.81) X (1.52/HDL) 
Statistical analysis 
Statistical analyses were performed using SPSS 17.0 (SPSS Inc., 
Chicago, IL) software. Data is presented as mean±SD for continuous 
variables following a normal distribution, median (interquartile range) 
for non-normally distributed data and as proportions for categorical 
variables. To assess the ability of a variable to discriminate between 
patients with and without VAD, receiver operator characteristic (ROC) 
curves were constructed for VAI. In addition, for VAI, a number of 
other diagnostic statistics such as sensitivity, specificity, positive 
likelihood ratio and negative likelihood ratio at various cut-points 
were measured. Statistical comparisons of patients with and without 
VAD were taken for all demographic variables, unpaired t-test or 
Mann–Whitney U test was used for continuous variables, depending 
on whether relevant distributional assumptions were met. Linear 
regression analysis was performed to evaluate the merit of VAI cut 
point in predicting hepatic insulin resistance. A two-tailed P 
value<0.05 was considered statistically significant. 
RESULTS  
Characteristics of the participants 
Clinical, biochemical and anthropometric characteristics of the 
participants are given in table 1. Participants were subdivided into 
two groups, healthy controls (35 males and 13 females) and 
overweight/obese type 2 diabetics (46 males and 35 females). 
  
Parameters 
Table 1: Baseline, clinical, anthropometric and biochemical characteristics of participants 
Controls N = 48 (M: F 35:13) Diabetics N = 81 (M: F 46:35) P-value 
Age (years) 34.5 (31, 41.5) 52.0 (45.5, 57) <0.01 
BMI (Kg/m2) 21.8 (20.3, 22.6) 27.5 (25.4, 30.5) <0.01 
Waist circumference (cm) 80.6 (6.2) 97.5 (9.4) <0.01 
Visceral fat (cm2) 70.2 (50.3) 148.6 (50) <0.01 
Fasting glucose (mg/dl) 93.9 (84.8, 108.6) 132.1 (105.8, 172.7) <0.01 
HbA1C (%) 5.5 (5.2, 5.7) 7.4 (6.5, 8.5) <0.01 
Fasting insulin (µU/ml) 7.3 (4.3, 10.7) 17.3 (10.2, 40.2) <0.01 
HOMA-IR 1.67 (0.94, 2.6) 5.4 (2.61, 14.9) <0.01 
Total cholesterol (mg/dl) 163 (38.50) 195.4 (40.5) <0.01 
TG (mg/dl) 81.2 (60.6, 100.6) 177.2 (114.3, 242.6) <0.01 
LDLc (mg/dl) 98.5 (30.3) 108.7 (29.8) 0.067 
HDLc (mg/dl) 41 (33.9, 46.5) 40.8 (35.4, 47.3) 0.886 
Non-HDLc (mg/dl) 120.9 (35.0) 152.9 (39.9) <0.01 
Apolipoprotein B (mg/dl) 75.1 (55, 99.6) 83.6 (69.6, 107.8) <0.05 
Apolipoprotein A1 (mg/dl) 118.3 (29.7) 132.6 (23.4) <0.05 
Apolipoprotein B/A1 ratio 0.70 (0.49, 0.86) 0.62 (0.53, 0.85) 0.918 
Visceral adiposity index (VAI) 1.13 (0.87, 1.8) 3.1 (1.7, 4.5) <0.01 
Data distributed normally are shown as mean (SD), whereas non-normally distributed data are shown as median (25% percentile, 75% percentile). 
Continuous variable compared using the unpaired t-tests or Mann-Whitney U tests depending on whether data met the relevant distributional assumptions. 
Pathak et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 8, 297-301 
 
299 
Participants in the diabetes group had significantly higher BMI and 
waist circumference than the healthy controls. Pathophysiologically, 
diabetes group demonstrated higher fasting glucose and fasting 
insulin levels. Consecutively, they were significantly insulin resistant 
with HOMA-IR of 5.4 (IQR = 2.61, 14.9) in the diabetes group vs 1.67 
(IQR = 0.94, 2.6) in healthy controls. In addition to being 
overweight/obese and insulin resistant, participants in the diabetes 
group demonstrated multiple CMR factors with significantly high TG, 
i.e. 177.2 mg/dl (IQR = 114.3, 242.6) vs 81.2 mg/dl (IQR = 60.6, 
100.6) in healthy controls, total cholesterol concentration, i.e. 195.4 
mg/dl (SD = 40.5) vs 163 mg/dl (SD = 38.50) in healthy controls and 
non-HDLc, i.e. 152.9 mg/dl (SD = 39.9) vs 120.9 mg/dl (SD = 35.0) in 
the healthy control group (table 1). Dyslipidemic diabetes group also 
showed significant deranged lipoprotein levels with higher 
apolipoprotein B value of 83.6 mg/dl (IQR = 69.6, 107.8) vs 75.1 
mg/dl (IQR = 55, 99.6) in the control group. 
 
 
The mean visceral fat value was significantly (p<0.001) lower in the 
healthy control group (70.2±50.3 cm2) as compared to the diabetes 
group (148.6±50 cm2). The distribution of visceral fat within the 
diabetes group is shown in fig. 1, which clearly indicates the 
predominance of high visceral fat among diabetics. Over 80% of the 
participants in diabetes group had visceral fat>100 cm2. Thus, 
visceral fat cut-off of 130 cm2 was chosen to explore the VAI value 
indicative of severity of metabolic disturbances (VAD) within 
diabetics predisposing them to higher CMR.  
Fig. 1: Distribution of visceral fat (cm2) in diabetes group 
 
In concurrence with the above observations, participants in the 
diabetes group had significantly higher VAI, i.e. 3.1 (IQR = 1.7, 4.5) vs 
1.13 (IQR = 0.87, 1.8) than the healthy controls. 
ROC curve and cut off determining VAD 
ROC curves were constructed and an area under the ROC curve 
(AUROC) with a measure of visceral fat area ≥130 cm2 on MRI (fig. 2) 
representing higher CMR was estimated. VAI could discriminate 
participants with and without VAD. The AUROC for VAI was 0.761 at 




Fig. 2: Receiver operating characteristics (ROC) analysis of VAI 
to predict the absence or presence of VAD as defined by visceral 
fat value of ≥130 cm2 on MRI 
Table 2 gives the sensitivity, specificity, positive likelihood ratios and 
negative likelihood ratios for the range of 0.25 unit intervals for VAI. 
The optimal cutoff point to predict visceral adiposity was 2.0, which 
yielded a sensitivity of 73.21% with a negative likelihood ratio of 0.38 
and specificity of 71.23% with a positive likelihood ratio of 2.55. 
  
VAI values 
Table 2: Diagnostic accuracy of VAI at various cut points 
Se Sp +LHR -LHR PPV NPV 
≥ 0.50 100 2.74 1.03 0 44.09 100 
≥ 0.75 100 15.07 1.18 0 47.46 100 
≥ 1.00 94.64 30.14 1.35 0.18 50.96 88 
≥ 1.25 91.07 38.36 1.48 0.23 53.12 84.85 
≥ 1.50 85.71 50.68 1.74 0.28 57.14 82.22 
≥ 1.75 78.57 60.27 1.98 0.36 60.27 78.57 
≥ 2.00 73.21 71.23 2.55 0.38 66.13 77.61 
≥ 2.25 69.64 75.34 2.82 0.4 68.42 76.39 
≥ 2.50 66.07 79.45 3.22 0.43 71.15 75.32 
≥ 2.75 58.93 79.45 2.87 0.52 68.75 71.6 
≥ 3.00 48.21 79.45 2.35 0.65 64.29 66.67 
≥ 3.25 42.86 83.56 2.61 0.68 66.67 65.59 
≥ 3.50 42.86 86.3 3.13 0.66 70.59 66.32 
≥ 3.75 37.5 87.67 3.04 0.71 70 64.65 
≥ 4.00 33.93 90.41 3.54 0.73 73.08 64.08 
≥ 4.25 30.36 93.15 4.43 0.75 77.27 63.55 
≥ 4.50 26.79 93.15 3.91 0.79 75 62.39 
 
Characteristics of diabetics based on VAI cut off 
Using the VAI cut off 2.0, participants in the diabetes group were 
divided into two groups; VAI<2.0 (DM+VAD absent group) and other 
with VAI ≥2.0 (DM+VAD present group).  
Se = sensitivity; Sp = specificity; +LHR = positive likelihood ratio; -LHR = negative likelihood ratio; PPV = positive predictive value; NPV = negative 
predictive value 
Both the groups did not differ significantly in age and BMI (as given in 
table 3). However, DM+VAD present group showed significantly 
(p<0.05) larger waist circumference, i.e. 96 cm (IQR = 93, 104.8) vs 92 
cm (IQR = 87.5, 102) in DM+VAD absent group and high visceral fat 
area, i.e. 157.1±49.1 cm2 vs 129.6±47.8 cm2 in DM+VAD absent group.
Pathak et al. 




Table 3: Baseline characteristics of DM+VAD absent and DM+VAD present patients 
Diabetes group P-value 
VAI<2.0  
(DM+VAD absent) N = 25 (M: F 16:9) 
VAI ≥ 2.0  
(DM+VAD present) N=56 (M: F 30:26) 
Age (years) 53.7 (6.6) 50 (8.5) 0.056 
BMI (Kg/m2) 26.4 (24.7, 29.4) 28.4 (25.8, 30.5) 0.121 
Waist circumference (cm) 92 (87.5, 102) 96 (93, 104.8) <0.05 
Visceral fat area (cm2) 129.6 (47.8) 157.1 (49.1) <0.05 
Fasting glucose (mg/dl) 124.8 (103.1, 138) 138.3 (104.7, 186.9) 0.56 
HbA1C (%) 7.7 (6.8, 8.4) 7.3 (6.4, 8.6) 0.898 
Fasting insulin (µU/ml) 10.8 (6.1, 31.1) 20.1 (11.5, 52.5) <0.05 
HOMA-IR 3.6 (1.7, 10.1) 7.8 (3.2, 19.1) <0.05 
Total cholesterol (mg/dl) 185.7 (40.3) 199.6 (40.3) 0.155 
TG (mg/dl) 102.2 (78, 118.9) 215 (168.4, 269.4) <0.01 
LDLc (mg/dl) 101 (27.50) 112.1 (30.4) 0.122 
HDLc (mg/dl) 51.4 (43.7, 57.2) 37.5 (34.8, 42) <0.01 
Non-HDLc (mg/dl) 134.9 (37.8) 160.9 (38.4) <0.05 
Apolipoprotein B (mg/dl) 78.4 (57.6, 86.6) 86.2 (74, 116.9) 0.154 
Apolipoprotein A1 (mg/dl) 142 (24.3) 128.4 (21.9) <0.05 
Apolipoprotein B/A1 ratio 0.55 (0.37, 0.66) 0.69 (0.56, 0.910 <0.05 
VAI 1.46 (0.9, 1.6) 3.9 (3.0, 5.6) <0.01 
 
Data distributed normally are shown as mean (SD), whereas non-normally distributed data are shown as median (25% percentile, 75% percentile). 
Continuous variable compared using the unpaired t-tests or Mann-Whitney U tests depending on whether data met the relevant distributional 
assumptions 
Participants of both the groups were type 2 diabetics having raised 
HbA1C levels and fasting glucose levels, which did not differ 
significantly (refer table 3). However, VAI could divide the group (VAI 
≥ 2.0) having statistical significant (p<0.05) difference in serum 
insulin, i.e. 20.1 µU/ml (IQR = 11.5, 52.5) vs 10.8 µU/ml (IQR = 6.1, 
31.1) in DM+VAD absent group and HOMA-IR value of 7.8 (IQR = 3.2, 
19.1) vs 3.6 (IQR = 1.7, 10.1) in DM+VAD absent group was observed. 
Consecutively, VAI cut-off of 2.0 could distinguish the diabetic 
participants with adiposity related raised CMR. DM+VAD present 
group had significantly (p<0.001) raised TG value, i.e. 215 mg/dl 
(IQR = 168.4, 269.4) vs 102.2 mg/dl (IQR = 78, 118.9) and low HDLc, 
i.e. 37.5 mg/dl (IQR = 34.8, 42) vs 51.4 mg/dl (IQR = 43.7, 57.2) 
compared participants in DM+VAD absent group respectively. 
Furthermore, DM+VAD present group had significantly (p<0.05) 
higher non-HDLc levels, i.e. 160.9±38.4 vs 134.9±37.8 mg/dl and 
apolipoprotein B/A1 ratio, i.e. 0.69 (IQR = 0.56, 0.910) vs 0.55 (IQR = 
0.37, 0.66) compared to DM+VAD absent group respectively.  
Performance of VAI in predicting hepatic insulin resistance 
The age-adjusted partial correlation coefficient of VAI, BMI and 
waist circumference with hepatic insulin resistance estimated using 
HOMA-IR was 0.32, 0.31 and 0.35 respectively. The correlation of 
these measures with insulin resistance was comparable and 
significant (p<0.001). Further, the results of logistic regression 
analysis for predicting hepatic insulin resistance using VAI had odds 
ratio of 5.6 (95% CI of 2.6–12.2). 
DISCUSSION  
In this study, the use of VAI to determine any given individual’s 
probability of having visceral adiposity dysfunction, based on simple 
clinical parameters was explored. The VAI cut off was explored in a 
relatively large cohort of individuals with varying degrees of obesity 
(including both healthy and overweight/obese diabetic participants) 
with and without visceral adiposity dysfunction as defined using 
visceral fat area less than or greater than equal to 130 cm2 measured 
using MRI technique.  
The study compared clinical indices between healthy controls and 
overweight/obese diabetic group. It is well established that type 2 
diabetic patients are predisposed to high CMR, and obesity has been 
implicated in the pathogenesis of CMR [18, 19]. Our study results 
confirm this i.e. the baseline characteristics of dysglycemic, insulin 
resistant and hyperinsulinemic overweight/obese diabetic group had 
additional CV risk factors linked to atherogenic dyslipidemia i.e. raised 
total cholesterol, TG, non-HDLc, apolipoprotein B and apolipoprotein 
B/A1 ratio compared to participants in healthy controls. Further, 
diabetic group had significantly elevated visceral fat values, i.e. 
148.6±50 vs 70.2±50.3 cm2 healthy controls and same was reflected 
in VAI values of 3.1 vs 1.13 in the healthy control group. 
Although VAI is simple to derive and well correlated with visceral fat 
accumulation, there is no definite value which can reflect visceral fat 
values corresponding to visceral adiposity dysfunction. In this study, an 
optimal VAI cutoff point for visceral adiposity dysfunction (defined as 
VFA greater than 130 cm2 by MRI) is established and this value was 2.0.  
One of the features of diabetes is abdominal obesity, and the visceral 
adiposity plays an important role in the progression of diabetes. VAI 
is strongly associated with incident diabetes. In this study, we found 
that DM+VAD present group was significantly more 
hyperinsulinemic and insulin resistant compared to diabetic group 
without VAD. DM+VAD present group also had more predominant 
components of metabolic syndrome as reflected by significantly high 
TG and low HDLc levels. Further, this group had significantly high 
non-HDLc and apolipoprotein B/A1 ratio. Collectively, DM+VAD 
present group was more insulin resistant, hyperinsulinemic, 
dyslipidemic group predisposed to cardiovascular risk as compared 
to DM+VAD absent group. Age adjusted partial correlation between 
VAI and HOMA-IR (r = 0.32) was found to be significant (p<0.001).  
CONCLUSION 
Metabolic parameters were deranged in overweight/obese diabetics 
than healthy controls. VAI as a simple indicator of visceral adipose 
dysfunction was strongly associated with the severity of obesity-
related CMR. The optimal cutoff point of VAI for predicting VAD was 
found to be 2.0 having a sensitivity of 73.21% and specificity 
71.23%. This cut-off point of VAI was useful in distinguishing 
diabetic patients with greater CMR. The VAI also showed good 
correlation with hepatic insulin resistance measured using HOMA-IR 
after adjusting the age. Thus, we suggest that the VAI would be an 
easy tool for the evaluation of the CMR in type 2 diabetes or in other 
populations, mainly in the absence of an overt metabolic syndrome. 
Further, this data also suggests that VAI can replace specialized 
imaging procedures with the advantages of a reduced economic 
burden and radiation hazard. However, it is necessary to identify the 
age-and sex-specific cutoff points in the general population for early 
diagnosis and individualized therapeutic programs in persons at risk 
for CVD, which is in progress. 
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